جستجوی مقالات مرتبط با کلیدواژه « کدون 72 ژن p53 » در نشریات گروه « پزشکی »

Breast cancer is the second most common cause of cancer death in women worldwide. Different epigenetic and genetic factors are associated with the development of breast cancer. Controversial results have been reported for oncogenic role of allelic polymorphism of the codon 72 of the p53 gene. Therefore، this study aimed to detect genotypic polymorphisms of p53 codon 72 in women with invasive ductal carcinoma in Sabzevar، Iran. This case-control study was conducted on 160 samples، 80 cancerous patients and 80 matched healthy controls. DNA was amplified using the two pairs of specific primers of p53 codon 72. The genotype of the p53 gene was determined using electrophoresis. The mean age of the patients and healthy controls were 47. 22±12. 95 and 48. 02± 12. 48، respectively. The frequencies of the heterozygote argenine/proline in the cancerous samples and controls were 49 (30. 6%) and 51 (31. 9%)، respectively. The frequencies of the homozygote argenine/argenine genotype in the cancerous and healthy ones were 29 (18. 1%) and 15 (9. 4%)، respectively. The frequencies of the homozygote proline/proline genotype in the patients and controls were 2 (1. 3%) and 14 (8. 8%)، respectively which showed a significant difference in this genotype between the two groups. Results indicate that carcinogenesis of breast cancer can be affected by different genotypes of codon 72 of the p53 gene. Hence، the detection of the allelic polymorphisms of codon 72 of the p53 gene is a valuable tool for predicting progress، prognosis and treatment purposes.

The P53 tumor suppressor gene plays important roles in genomic stability. G–to-C at codon 72 in the P53 gene has been associated with increased risk for lung, oral, prostate, breast, colorectal cancers and may be a marker for risk of skin cancer. This project studied the effect of P53 polymorphism on risk of nonmelanoma skin cancers (Squamous and basal cell carcinoma). This case–control study undertook for study of twenty basal cell carcinoma (BCC), twenty squamous cell carcinoma (SCC) and twenty specimens as controls for each cancer specimen in the city of Isfahan, Iran. Different P53 codon 72 genotypes were identified using polymerase chain reaction. In control samples, the frequency of Arg/Arg genotype showed 25% and in BCC specimens showed 60%. The differences in this genotype group between the cases and controls were statistically significant (P = 0.048). The differences in the frequency of heterozygot Arg/Pro and also in the frequency of Pro/Pro genotype between the cases and controls were not statistically significant. OR = 4.5 in BCC cases show that the risk for this disease in persons who have Arg/Arg genotype is about 4.5 times more than normal people. The results of χ2 test showed that in this study there is not statistically significant differences between the SCC specimens and controls for frequency of different genotypes. The present study indicate that P53 codon 72 polymorphism is a genetic predisposing factor for risk of nonmelanoma skin cancers (of BCC type) in Isfahan. However, further studies are needed in order to elucidate the role of P53 codon 72 polymorphism in skin cancer development.

The p53 tumor suppressor gene plays an important role in genomic stability. A common G-to-C polymorphism at codon 72 in the p53 gene has been accompanied with high risk of lung, nasopharyngeal, oral, prostate, and colorectal cancers, and may result in genetic susceptibility to breast cancer. We studied the effect of this p53 polymorphism on breast invasive ductal carcinoma development This case–control study was conducted among 51 patients with breast invasive ductal carcinoma and 51 matched controls in Isfahan. P53 codon 72 genotypes were identified using allele-specific polymerase-chain reaction (PCR). In control samples, the genotype distribution of p53 polymorphism showed 43.2%, 52.9% and 3.9% for the Arg/Arg, Arg/Pro and Pro/Pro genotypes, respectively. In cancer group the distribution was 86.2% for Arg/Arg, 11.8% for Arg/Pro and 2% for Pro/Pro. Distribution differences in p53 codon 72 polymorphism between the cases and controls were statistically significant (P)